KR20250053870A - 톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법 - Google Patents
톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법 Download PDFInfo
- Publication number
- KR20250053870A KR20250053870A KR1020257007164A KR20257007164A KR20250053870A KR 20250053870 A KR20250053870 A KR 20250053870A KR 1020257007164 A KR1020257007164 A KR 1020257007164A KR 20257007164 A KR20257007164 A KR 20257007164A KR 20250053870 A KR20250053870 A KR 20250053870A
- Authority
- KR
- South Korea
- Prior art keywords
- cell lymphoma
- decitabine
- tolinapant
- lymphoma
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263374137P | 2022-08-31 | 2022-08-31 | |
| US63/374,137 | 2022-08-31 | ||
| PCT/IB2022/060652 WO2024047394A1 (en) | 2022-08-31 | 2022-11-04 | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250053870A true KR20250053870A (ko) | 2025-04-22 |
Family
ID=84359488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257007164A Pending KR20250053870A (ko) | 2022-08-31 | 2022-11-04 | 톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082286A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4580635A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025529240A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250053870A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022476674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3266274A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025002312A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202410893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024047394A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| LT4069254T (lt) * | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
-
2022
- 2022-11-04 JP JP2025513127A patent/JP2025529240A/ja active Pending
- 2022-11-04 TW TW111142283A patent/TW202410893A/zh unknown
- 2022-11-04 AU AU2022476674A patent/AU2022476674A1/en active Pending
- 2022-11-04 KR KR1020257007164A patent/KR20250053870A/ko active Pending
- 2022-11-04 CA CA3266274A patent/CA3266274A1/en active Pending
- 2022-11-04 WO PCT/IB2022/060652 patent/WO2024047394A1/en not_active Ceased
- 2022-11-04 EP EP22805975.4A patent/EP4580635A1/en active Pending
-
2023
- 2023-08-30 US US18/458,884 patent/US20240082286A1/en active Pending
-
2025
- 2025-02-26 MX MX2025002312A patent/MX2025002312A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4580635A1 (en) | 2025-07-09 |
| WO2024047394A1 (en) | 2024-03-07 |
| AU2022476674A1 (en) | 2025-04-17 |
| MX2025002312A (es) | 2025-04-02 |
| JP2025529240A (ja) | 2025-09-04 |
| TW202410893A (zh) | 2024-03-16 |
| US20240082286A1 (en) | 2024-03-14 |
| CA3266274A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3052607T3 (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| US12208141B2 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| US20230364086A1 (en) | Combination therapies with ehmt2 inhibitors | |
| KR20250167002A (ko) | Kras 조절 화합물 | |
| BR102019002873A2 (pt) | inibidores de pd-1/pd-l1 | |
| US9464093B2 (en) | Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer | |
| CN116113406B (zh) | Gas41抑制剂及其使用方法 | |
| RS64936B1 (sr) | Metodi lečenja hematoloških maligniteta korišćenjem 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benz il)amino-)izoindolin 1,3-diona | |
| JP2024542248A (ja) | Fgfr阻害剤とkras阻害剤を含む併用療法 | |
| CN118488946A (zh) | Ikaros锌指家族降解剂及其用途 | |
| CN118488948A (zh) | Ikaros锌指家族降解剂及其用途 | |
| CN118591537A (zh) | Parp7抑制剂 | |
| US20240082286A1 (en) | Combination therapies for treatment of t-cell lymphomas | |
| US20250186451A1 (en) | Methods of treating cancer with iap antagonist compounds and combination therapies | |
| CN103635183A (zh) | 使用pi3k/mtor的吡啶并嘧啶抑制剂来治疗淋巴瘤的方法 | |
| HK40121467A (en) | Kras g12d modulating compounds | |
| CN120112288A (zh) | 用于治疗肿瘤的药物组合、药物组合物及其用途 | |
| JP2024539641A (ja) | 癌の治療に使用するための変異retキナーゼの阻害剤 | |
| HK40111208B (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| HK40114167A (en) | Ikaros zinc finger family degraders and uses thereof | |
| HK40114166A (en) | Ikaros zinc finger family degraders and uses thereof | |
| HK40058418B (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| HK40083716A (en) | Diacylglycerol kinase modulating compounds | |
| HK40058418A (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20250304 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |